DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2008/0051758 A1 Rioux Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2008/0051758 A1 Rioux Et Al US 20080051758A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2008/0051758 A1 Rioux et al. (43) Pub. Date: Feb. 28, 2008 (54) MEDICAL DEVICES (21) Appl. No.: 11/458,171 (75) Inventors: Robert F. Rioux, Ashland, MA (22) Filed: Jul. 18, 2006 (US); David J. Sauvageau, Methuen, MA (US) Publication Classification Correspondence Address: ( 51) Int. Cl. FSH & RICHARDSON PC A6M 3L/00 (2006.01) P.O. BOX 1022 (52) U.S. Cl. ....................................................... 6O4/509 MINNEAPOLIS, MN 55440-1022 (57) ABSTRACT (73) Assignee: BOSTON SCIENTIFIC SCIMED, INC., Maple Grove, Medical devices, and related components and methods, are MN (US) disclosed. Patent Application Publication Feb. 28, 2008 Sheet 1 of 10 US 2008/0051758A1 - Ya-a-a- ..……*** - *****-----.…... k *********~~~~….…***** ...º.………·~~~~-….….---******* ...…--~~~~*~~~~ -…--~~~” Patent Application Publication Feb. 28, 2008 Sheet 2 of 10 US 2008/0051758A1 Patent Application Publication Feb. 28, 2008 Sheet 3 of 10 US 2008/0051758A1 Patent Application Publication US 2008/0051758A1 Patent Application Publication Feb. 28, 2008 Sheet 5 of 10 US 2008/0051758A1 F. G. 2D Patent Application Publication Feb. 28, 2008 Sheet 6 of 10 US 2008/0051758A1 FG. 3B Patent Application Publication Feb. 28, 2008 Sheet 7 of 10 US 2008/0051758A1 **********************~~~~~~~~========.=…-.-.-.-.-.-.-.-.-.-.-.-.-.-.-.-.-.-.-.-.-.-.-.-.-.- ·****************************. o,,,~~~ Patent Application Publication Feb. 28, 2008 Sheet 8 of 10 US 2008/0051758A1 G. 5B Patent Application Publication Feb. 28, 2008 Sheet 9 of 10 US 2008/0051758A1 F.G. 5C Patent Application Publication Feb. 28, 2008 Sheet 10 of 10 US 2008/0051758A1 US 2008/0051758 A1 Feb. 28, 2008 MEDICAL DEVICES the lumen of the generally tubular member, and/or at least one contrast agent can be flowed through the lumen of the TECHNICAL FIELD generally tubular member. The method can include viewing the embolic material (e.g., within the lumen of the subject) 0001. This invention relates to medical devices, and to using X-ray fluoroscopy. The method can include resecting related components and methods. liver tissue of the subject. BACKGROUND 0009 Curving the portion of the generally tubular mem ber that carries the inflatable member can include removing 0002 Therapeutic vascular occlusions (embolizations) an inner member from the lumen of the generally tubular are used to prevent or treat pathological conditions in situ. member, and/or disposing an inner member into the lumen Compositions including embolic particles are used for of the generally tubular member. The inner member can occluding vessels in a variety of medical applications. include a needle, a guidewire, a stylet, or a combination Embolic particles can be delivered to a target site in a body thereof. Curving the portion of the generally tubular member of a Subject using, for example, a catheter. that carries the inflatable member can include inflating the inflatable member and/or aligning the portion of the gener SUMMARY ally tubular member with a longitudinal axis of the lumen of 0003. In one aspect, the invention features a method that the subject. includes delivering a catheter into a lumen of a Subject. The 0010. The method can include inflating the inflatable catheter includes a generally tubular member having a member. The method can include delivering at least one lumen, a proximal region, and a distal region, and an embolic material and/or contrast agent into the lumen of the inflatable member carried by a portion of the generally generally tubular member during and/or after inflation of the tubular member. The method also includes curving the inflatable member. When inflated, the inflatable member can portion of the generally tubular member that carries the have a diameter of at least about one centimeter (e.g., at least inflatable member within the lumen of the subject, and about two centimeters, at least about three centimeters) disposing at least one embolic material into the lumen of the and/or at most about four centimeters (e.g., at most about generally tubular member. three centimeters, at most about two centimeters). The 0004. In another aspect, the invention features a method inflatable member can have a wall including at least two that includes delivering a catheter into a lumen of a subject. regions with different thicknesses. The inflatable member The catheter includes a generally tubular member having a can be eccentrically disposed on the portion of the generally lumen, a proximal region, and a distal region, and an tubular member that carries the inflatable member. inflatable member carried by a portion of the generally 0011. The distal region of the generally tubular member tubular member. The method also includes curving the can include a distal end of the generally tubular member, and portion of the generally tubular member that carries the the lumen of the generally tubular member can extend inflatable member within the lumen of the subject, and through the distal end of the generally tubular member. flowing at least one contrast agent into the lumen of the 0012. The lumen of the subject can be a branch of a portal generally tubular member. vein. The lumen of the Subject can have a longitudinal axis. 0005. In an additional aspect, the invention features a Delivering the catheter into the lumen of the subject can method of resecting liver tissue of a subject. The method include inserting the catheter into the lumen of the subject includes delivering a catheter into a lumen of a Subject. The along an axis that is perpendicular to the longitudinal axis of catheter includes a generally tubular member having a the lumen of the subject. Delivering the catheter into the lumen, a proximal region, and a distal region, and an lumen of the Subject can include inserting the catheter inflatable member that is carried by a portion of the gener through a location in the skin of the Subject and through a ally tubular member. The method also includes inflating the location in the lumen of the subject. The location in the inflatable member within the lumen of the subject, curving lumen of the subject can be located at most about three the portion of the generally tubular member that carries the millimeters (e.g., at most about two millimeters, at most inflatable member within the lumen of the subject, disposing about one millimeter), and/or at least about 0.1 millimeter embolic particles into the lumen of the generally tubular (e.g., at least about 0.5 millimeter, at least about one member, delivering the embolic particles into the lumen of millimeter), from the location in the skin of the subject. the Subject, and resecting liver tissue of the Subject. 0013 Embodiments can include one or more of the 0006 Embodiments can also include one or more of the following advantages. following. 0014. The method can be used to deliver one or more 0007. The embolic material can include one or more embolic materials, contrast agents, and/or therapeutic agents embolic gels, embolic particles, and/or embolic coils. The to a target site (e.g., a lumen of a subject) effectively and embolic particles can have an arithmetic mean diameter of efficiently. Curving the distal region of the generally tubular about 3,000 microns or less and/or about one micron or member can allow the embolic materials, contrast agents, O. and/or therapeutic agents to be delivered into the target site 0008. The method can include disposing at least one relatively easily and/or in a relatively high volume. embolic material into the lumen of the generally tubular 0015 The method can include embolizing one or more member, and/or delivering at least one embolic material into branches of a portal vein. The embolization of the branches the lumen of the subject. The method can include rotating of the portal vein can be executed relatively efficiently and the portion of the generally tubular member that carries the with a relatively low likelihood of harm to the subject (e.g., inflatable member within the lumen of the subject. During with a relatively low likelihood of perforation of the walls of and/or after rotation of the portion of the generally tubular the branches). In some embodiments, one or more branches member, at least one embolic material can be disposed into of a portal vein of a subject can be embolized prior to a liver US 2008/0051758 A1 Feb. 28, 2008 resection procedure. This can, for example, enable one or 0032 FIG.5D illustrates the inflation of the balloon of more segments of the liver of the subject to be resected with the balloon catheter of FIG. 5C, and the delivery of embolic relatively little blood loss, and/or enable one or more non material through the balloon catheter and into the lumen of resected segments of the liver of the Subject to experience a the subject. relatively high rate of growth. 0033 FIG. 5E is a cross-sectional view of the lumen of 0016. The distance between the point at which the cath the subject of FIGS.5A-5D, after embolic material has been eter enters the body of a subject and the point at which the delivered into the lumen of the subject. catheter enters a target site (e.g., a lumen of the Subject, Such as a branch of a portal vein) can be relatively short. As a DETAILED DESCRIPTION result, the catheter can be delivered into a target site without 0034 FIG. 1 shows a liver 10 of a subject 12, as well as having to navigate a long distance within the body of the a portal vein 14, a Superior mesenteric vein 16, an inferior Subject first. This can, for example, reduce procedure time mesenteric vein 18, a splenic vein 20, and a gastric vein 22.
Load more

Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2005/0129775 A1 Lanphere Et Al
    US 2005O129775A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2005/0129775 A1 Lanphere et al. (43) Pub. Date: Jun. 16, 2005 (54) FERROMAGNETIC PARTICLES AND (22) Filed: Aug. 27, 2004 METHODS Related U.S. Application Data (75) Inventors: Janel Lanphere, Pawtucket, RI (US); Erin McKenna, Boston, MA (US); (63) Continuation-in-part of application No. 10/651,475, Thomas V. Casey II, Grafton, MA filed on Aug. 29, 2003. (US) Publication Classification Correspondence Address: FISH & RICHARDSON PC (51) Int. Cl." ........................... A61K 9/127; A61K 9/14; 225 FRANKLIN ST A61K 33/26 BOSTON, MA 02110 (US) (52) U.S. Cl. ............................................ 424/489; 424/646 (73) ASSignee: Siedle Systems, Inc., Maple (57) ABSTRACT (21) Appl. No.: 10/928,452 Ferromagnetic particles and methods are disclosed. Patent Application Publication Jun. 16, 2005 Sheet 1 of 5 US 2005/0129775 A1 Patent Application Publication Jun. 16, 2005 Sheet 2 of 5 US 2005/0129775 A1 s nS) l r N. 1 Yn ESDNIAJ?SdWßd N-EZT| 1 - - - - - - - - - - - - - - - - - - - - - - - - - a - - a - - - - Patent Application Publication Jun. 16, 2005 Sheet 3 of 5 US 2005/0129775 A1 : 3 L D Cl U c). Z Y X C) Patent Application Publication Jun. 16, 2005 Sheet 4 of 5 US 2005/0129775 A1 s s Patent Application Publication Jun. 16, 2005 Sheet 5 of 5 US 2005/0129775 A1 26SS EMBOLIC PARTICLES FIBROID jS. 111 UTERINE ARTERY CATHETER 150 FIG. R., US 2005/0129775 A1 Jun. 16, 2005 FERROMAGNETIC PARTICLES AND METHODS 0011 Heating a particle can include exposing the particle to RF radiation. CROSS-REFERENCE TO RELATED 0012.
    [Show full text]
  • Supplement 12
    APPROVED DRUG PRODUCTS with THERAPEUTIC EQUIVALENCE EVALUATIONS 14TH EDITION Cumulative Supplement 1 2 DECEMBER 1994 CONTENTS PAGE 1.0 INTRODUCTION............................................. iii 1.1 Ilow to Use the Cumulative Supplement .. iii 1.2 Products Requiring Revised Labeling for Full Approval . v 1.3 Applicant Name Changes. vi 1.4 New Indications for Previously Approved Drug Products ............... vii 1 .5 USP Monograph Title Additions or Changes . ix 1.6 Report of Counts for the Prescription Drug Product List. x 2.0 DRUG PRODUCT LISTS ....................................... 2.1 Prescription Drug Product List ................................. 1 2.2 OTC Drug Product List ...................................... 61 2.3 Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List. 63 2.4 Orphan Drug Product Designations . 64 2.5 Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution ................ 70 2.6 Biopharmaceutic Guidance Availability ........................... 71 2.7 ANDA Suitability Petitions . 72 PATENT AND EXCLUSIVITY INFORMATION ADDENDUM A. Exclusivity Terms. 74 B. Patent and Exclusivity Lists . 76 APPROVED DRUG PRODUCTS with THERAPEUTIC EQUIVALENCE EVALUATIONS 14TH EDITION CUMULATIVE SUPPLEMENT 12 DECEMBER 1994 1.0 INTRODUCTION 1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence
    [Show full text]
  • LGC Standards Pharmacopoeial Reference Standards 2014
    LL CTS INKSP RODUTO A L P ITH W WEBSHO LGC Standards Pharmacopoeial reference standards 2014 FOR STANDARDS WITH CofA SEE OUR CATALOGUE: PHARMACEUTICAL IMPURITIES AND PRIMARY REFERENCE STANDARDS LGC Quality – ISO Guide 34 • GMP/GLP • ISO 9001 • ISO/IEC 17025 • ISO/IEC 17043 Pharmaceutical impurities Code Product CAS No. CS Price Unit Adiphenine Hydrochloride O LGC Standards N O MM1172.00 Adiphenine Hydrochloride 50-42-0 A 250mg HCl Pharmaceutical impurities and Adrenaline Tartrate OH H OH O OH primary reference standardsMM0614.00 2014 N OH Adrenaline Tartrate 51-42-3 A 500mg OH OH O OH OH H MM0614.02 L-Adrenaline 51-43-4 A 500mg OH N OH Imp. C (EP) as Hydrochloride: 1-(3,4-Di- O H OH MM0614.13 hydroxyphenyl)-2-(methylamino)ethanone 62-13-5 A 100mg N HCl Hydrochloride (Adrenalone Hydrochloride) OH (1R)-1-(3,4-Dihydroxyphenyl)-2- OH O S O MM0614.01 methylaminoethanesulphonic Acid H 78995-75-2 A 100mg OH N (Adrenaline -Sulphonate) OH Alanine NH2 MM0566.00 Alanine 56-41-7 A 500mg OH O Imp. A (Pharmeuropa): (2 S)-2-Aminobutanedioic Acid O NH 2 MM0567.00 OH (Aspartic Acid) 56-84-8 A 500mg OH O Albendazole O H MM0382.00 Albendazole N O 54965-21-8 A 500mg N H S N Imp. A (EP): 5-(Propylsulphanyl)-1H- H MM0382.01 N 80983-36-4 A 100mg NH2 benzimidazol-2-amine S N O H Imp. B (EP): Methyl [5-Propylsulphinyl)- N O MM0382.02 N 54029-12-8 A 100mg H 1H-benzimidazol-2-yl]carbamate S N O O H Imp.
    [Show full text]
  • Iodine-Containing Drugs
    Iodine-containing drugs Iodine-containing drugs (iodine) usually have an iodine content of >5mg/tablet or ml. The antiarrhythmic agent amiodarone, for example, contains 75 mg iodine/tablet, 10 ml betaisodona solution about 110 mg . - The administration of X-ray contrast media is another important reason for excessive iodine exposure. X-ray contrast media frequently contain > 100 mg iodine/ml. Contrast media contain almost exclusively organically bound iodine, but in vivo these compounds are partially deiodinated (deiodinase) (Mann et al. Eur J. Endocrinol 1994; 130 (5): 498). Assuming that water-soluble contrast media is eliminated within 10 to 14 days, enzymatic separation of iodine nevertheless leads to an offer of about 14 to 175 mg in the thyroid. Fat-soluble contrast media applied in cholecystograms have a much longer half time in the organism, and iodine can consequently be separated long. The table of Surks et al. (New Engl J Med 1995; 333: 1688) gives a survey of the most important iodine preparations applied in the USA. Iodine Content of Some Iodine Containing Medications and Radiographic Contrast Agents SUBSTANCE AMOUNT OF IODINE Expectorants Iophen 25 mg/ml Organidin (iodinated glycerol) 15 mg/tablet Par Glycerol 5 mg/ml R-Gen 6 mg/ml Iodides Potassium iodide (saturated solution) -25 mg/drop Pima syrup (potassium iodide) 255 mg/ml Lugol's solution (potassium iodide -7 mg/drop + iodine) Iodo-Niacin 115 mg/tablet Antiasthmatic drugs Mudrane 195 mg/tablet Elixophyllin-KI (theophylline) elixir 6.6 mg/ml © Merck KGaA 2002 Iophylline 2 mg/ml Antiarrhythmic drugs Amiodarone 75 mg/tablet Antiamebic drugs Iodoquinol 134 mg/tablet Topical antiseptic agents Poidone-iodine 10 mg/ml Clioquinol 12 mg/g Douches Povidone-iodine 10 mg/ml Radiographic contrast agents Iopanoic acid 333 mg/tablet Ipodate sodium 308 mg/tablet Intravenous preparations 140-380 mg/ml M.J.
    [Show full text]
  • Summary and Recommendations for Thyroid Screening in Pregnancy: Is
    Gregory A. Brent, MD Departments of Medicine and Physiology David Geffen School of Medicine at UCLA Etiologies of Hypothyroidism • Chronic autoimmune thyroiditis-Hashimoto’s disease • Partial thyroidectomy. • Radioactive iodine therapy for treatment of hyperthyroidism. • External radiotherapy of the head and neck in patients with Hodgkin’s lymphoma, leukemia, brain tumors, or bone-marrow transplantation. • Infiltrative disorders of the thyroid gland (eg, amyloidosis, sarcoidosis,hemochromatosis, or Riedel’s thyroiditis). Modified from Cooper and Biondi Lancet 379:1142, 2012 Pearce and Braverman Best Pract Clin Endo Metab 23:801, 2009 Agent Example of Sources Mode of Action Thyroid Disease in Humans Polychlorinated Found in coolants and TR Possible increase in biphenyls (PCBs) lubricants, properties; agonist/antagonist, TSH, thyroid multiple congeners, can alter levels of T4 autoantibodies, thyroid lipophilic and TSH volume Organochlorine Used as pesticide on Induce hepatic No established pesticides crops glucuronyltransferase association (UDPGTs) Polybrominated Found in flame Bind to TRs, Increase in diphenylethers retardants displaces T4 from hypothyroidism in some (PBDEs) binding proteins studies Bisphenol-A (BPA) Used in plastic bottles Antagonize TR, lower No established serum T4 association Adapted from Brent GA Thyroid 20:755, 2010 Agent Example of Mode of Action Thyroid Disease Sources In Humans Perchlorate, Rocket fuel, Inhibits iodine No established Thiocyanate fertilizer, uptake, at sufficient association smoking levels reduces
    [Show full text]
  • PF 41(4) Table of Contents Publish Date: Jul 1, 2015
    PF 41(4) Table of Contents Publish date: Jul 1, 2015 PROPOSED IRA Proposed IRA Intro Section USP MONOGRAPHS Methocarbamol (1-Jan-2016) Protamine Sulfate Injection (1-Jan-2016) IN-PROCESS REVISION IPR Introduction GENERAL CHAPTERS <1130> NUCLEIC ACID-BASED TECHNIQUES—APPROACHES FOR DETECTING TRACE NUCLEIC ACIDS (RESIDUAL DNA TESTING) (USP39-NF34 2S) REAGENTS, INDICATORS, AND SOLUTIONS Reagent Specifications Carbon Tetrachloride (USP39-NF34 2S) 4-Hydroxy-4-phenylpiperidine [NEW] (USP39-NF34 2S) Monosodium Glutamate [NEW] (USP39-NF34 2S) 6Z-Retinoic Acid [NEW] (USP39-NF34 2S) Sulfaguanidine [NEW] (USP39-NF34 2S) Chromatographic Columns L## (Tretinoin, Cosmosil Cholesterol) [NEW] (USP39-NF34 2S) REFERENCE TABLES Container Specifications Containers for Dispensing Capsules and Tablets [NEW] (USP39-NF34 2S) Description and Solubility Description and Solubility of USP and NF Articles [NEW] (USP39-NF34 2S) Description and Solubility - C Description and Solubility - F Description and Solubility - M DIETARY SUPPLEMENT MONOGRAPHS Methylcobalamin Tablets [NEW] (USP39-NF34 2S) Northern Schisandra Fruit Dry Extract [NEW] (USP39-NF34 2S) PF 41(4) Table of Contents 1 | Page NF MONOGRAPHS Chlorobutanol (USP39-NF34 2S) Eucalyptus Oil (USP39-NF34 2S) USP MONOGRAPHS Albuterol Sulfate (USP39-NF34 2S) Alprazolam Extended-Release Tablets (USP39-NF34 2S) Alprazolam Orally Disintegrating Tablets (USP39-NF34 2S) Aminobenzoate Potassium (USP39-NF34 2S) Aminobenzoate Potassium Capsules (USP39-NF34 2S) Aminobenzoate Sodium (USP39-NF34 2S) Gamma-Aminobutyric Acid Capsules
    [Show full text]
  • Col11bined Index to USP 37 and NF 32, Volul11es 1-4
    ..... Combined Index to USP 37 and NF 32 Abaca-Aceto 1-1 COl11bined Index to USP 37 and NF 32, Volul11es 1-4 Page citations refer to the pages of Volumes 7, 2, 3, and 4 of uSP 37-NF 32. This index is repeated in its entirety in each volume. 1-1554 Volume 1 1555-3460 Volume 2 3461-5230 Volume 3 5231-6262 Volume 4 Numbers in angle brackets such as (421) refer to chapter numbers in the General Chapters section. and (salts of) chlorpheniramine, isometheptene mucate, and dextromethorphan, and dichloralphenazone capsules, 3416 phenylpropanolamine, oral solution and oxycodone capsules, 4141 Abacavir containing at least three of the and oxycodone tablets, 4142 oral solution, 1S5 5 following, 1576 and pentazocine tablets, 4231 sulfate, 1556 and (salts of) chlorpheniramine, and propoxyphene hydrochloride tablets, tablets, 1557 dextromethorphan, and 4458 Absolute phenylpropanolamine, tablets containing and propoxyphene napsylate tablets, 4463 alcohol, 1373 at least three of the following, 1577 and pseudoephedrine hydrochloride ether, 1372 and (salts of) chlorpheniramine, tablets, 1597 Absorbable dextromethorphan, and oral solution, 1566 dusting powder, 2745 pseudoephedrine, capsules containing at for effervescent oral solution, 1567 gelatin film, 3132 least three of the following, 1579 suppositories, 1567 gelatin sponge, 3132 and (salts of) chlorpheniramine, oral suspension, 1568 surgical suture, 4808 dextromethorphan, and tablets, 1569 Absorbent pseudoephedrine, oral powder extended-release tablets, 1570 cotton, 1372 containing at least three of
    [Show full text]
  • 1484 Contrast Media
    1484 Contrast Media myelography, see under Iohexol, p.1483; for specific references, to iodine or to other contrast media, severe hyperthyroidism, hy- Profile see below. peruricaemia, or cholangitis. Because of its cholinergic action, Iopentol is a nonionic monomeric iodinated radiographic con- Effects on the nervous system. Reports of serious neurolog- premedication with atropine has been suggested in some coun- trast medium (see p.1474). It may be given intravenously, intra- ical sequelae to lumbar myelography with iopamidol. tries for patients with coronary heart disease. Iodine-containing arterially, orally, or by instillation into body cavities, and is used contrast media may interfere with thyroid-function tests and with in procedures including angiography, arthrography, endoscopic 1. Wallers K, et al. Severe meningeal irritation after intrathecal in- jection of iopamidol. BMJ 1985; 291: 1688. some blood and urine tests. retrograde cholangiopancreatography, hysterosalpingography, urography, and visualisation of the gastrointestinal tract. It is also 2. Robinson C, Fon G. Adverse reaction to iopamidol. Med J Aust Breast feeding. No adverse effects have been observed in 1986; 144: 553. used for contrast enhancement in computed tomography. breast-feeding infants whose mothers were receiving iopanoic 3. Bell JA, McIlwaine GG. Postmyelographic lateral rectus palsy 1 associated with iopamidol. BMJ 1990; 300: 1343–4. acid and the American Academy of Pediatrics considers that it Iopentol is usually available as solutions containing 32.9 to 4. Mallat Z, et al. Aseptic meningoencephalitis after iopamidol my- is therefore usually compatible with breast feeding. 76.8% of iopentol (equivalent to 150 to 350 mg/mL of iodine) elography. Lancet 1991; 338: 252.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2002/0010208A1 Shashoua Et Al
    US 2002001 0208A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2002/0010208A1 Shashoua et al. (43) Pub. Date: Jan. 24, 2002 (54) DHA-PHARMACEUTICAL AGENT Related U.S. Application Data CONJUGATES OF TAXANES (63) Continuation of application No. 09/135,291, filed on (76) Inventors: Victor Shashoua, Brookline, MA (US); Aug. 17, 1998, now abandoned, which is a continu Charles Swindell, Merion, PA (US); ation of application No. 08/651,312, filed on May 22, Nigel Webb, Bryn Mawr, PA (US); 1996, now Pat. No. 5,795,909. Matthews Bradley, Layton, PA (US) Publication Classification Correspondence Address: Edward R. Gates, Esq. (51) Int. Cl." ............................................ A61K 31/337 Wolf, Greenfield & Sacks, P.C. (52) U.S. Cl. .............................................................. 514/449 600 Atlantic Avenue Boston, MA 02210 (US) (57) ABSTRACT The invention provides conjugates of cis-docosahexaenoic (21) Appl. No.: 09/846,838 acid and pharmaceutical agents useful in treating noncentral nervous System conditions. Methods for Selectively target 22) Filled: Mayy 1, 2001 ingg pharmaceuticalp agents9. to desired tissues are pprovided. Patent Application Publication Jan. 24, 2002 Sheet 1 of 14 US 2002/0010208A1 1 OO 5 O -5OO - 1 OO-9 -8 -7 -6 -5 -4 LOG-10 OF SAMPLE CONCENTRATION (MOLAR) CCRF-CEM-o- SR ----- RPM-8226----- K-562- - -A - - HL-60 (TB) -g- - MOLT4: ... O Fig. 1 1 OO 5 O -5OO -1 O O -8 -7 -6 -5 -4 -- 9 LOGo OF SAMPLE CONCENTRATION (MOLAR) A549/ATCC-o-NS326. NCEKVX 28. --Q-- NCI-H322M-...-a---Eidsf8::... NC-H522--O-- HOP-62---Fig. 2 a-- NC-H460.-------- Patent Application Publication Jan.
    [Show full text]
  • DRUG-INDUCED HYPOTHYROIDISM Drug-Induced Primary
    394 MEDICINA - VolumenISSN 77 - Nº1669-9106 5, 2017 SPECIAL ARTICLE MEDICINA (Buenos Aires) 2017; 77: 394-404 DRUG-INDUCED HYPOTHYROIDISM LEONARDO F. L. RIZZO1, DANIELA L. MANA1, HÉCTOR A. SERRA1, 2 1Dirección Médica Química Montpellier SA, 2Cátedra de Farmacología, Facultad de Ciencias Médicas, U.C.A., Buenos Aires, Argentina Abstract The thyroid axis is particularly prone to interactions with a wide variety of drugs, whose list increases year by year. Hypothyroidism is the most frequent consequence of drug-induced thyroid dysfunction. The main mechanisms involved in the development of primary hypothyroidism are: inhibition of the synthesis and/ or release of thyroid hormones, immune mechanisms related to the use of interferon and other cytokines, and the induction of thyroiditis associated with the use of tyrosine kinase inhibitors and drugs blocking the receptors for vascular endothelial growth factor. Central hypothyroidism may be induced by inhibition of thyroid-stimulating hormone (bexarotene or corticosteroids) or by immunological mechanisms (anti-CTLA4 or anti-PD-1 antibody drugs). It is also important to recognize those drugs that generate hypothyroidism by interaction in its treatment, either by reducing the absorption or by altering the transport and metabolism of levothyroxine. Thus, it is strongly recommended to evaluate thyroid function prior to the prescription of medications such as amiodarone, lithium, or interferon, and the new biological therapies that show important interaction with thyroid and endocrine function in general. Key words: thyroid, hypothyroidism, drugs Resumen Hipotiroidismo inducido por drogas. El eje tiroideo es particularmente proclive a sufrir interacciones con una amplia variedad de drogas, cuya lista se acrecienta año a año.
    [Show full text]
  • Revised References to Heavy Metals <231>
    Revised References to Heavy Metals <231> Targeted Official Date for Omission of References: 01-January-2018 Title File Type <3> Topical And Transdermal Drug Products--Product Quality Tests General Chapter <661> Containers--Plastics General Chapter <1059> Excipient Performance General Chapter <1086> Impurities In Drug Substances And Drug Products General Chapter <1151> Pharmaceutical Dosage Forms USP Acarbose USP Acebutolol Hydrochloride USP Acesulfame Potassium NF Acetaminophen USP Acetazolamide USP Acetic Acid NF Diluted Acetic Acid NF Glacial Acetic Acid USP & NF Acetohexamide USP Acetohydroxamic Acid USP Acetylcysteine USP & NF Acetyltributyl Citrate NF Acetyltriethyl Citrate NF Acetyltyrosine DS Acitretin USP Adapalene USP Adenine USP Adenosine USP S-Adenosyl-L-methionine Disulfate Tosylate DS Adipic Acid NF Agar NF Alanine USP & DS Alclometasone Dipropionate USP Alcohol in Dextrose Injection USP Alendronate Sodium USP Alfadex NF Alginic Acid NF Alprazolam USP Altretamine USP Ammonium Alum USP Potassium Alum USP Alumina and Magnesia Oral Suspension USP Alumina, Magnesia, and Calcium Carbonate Oral Suspension USP Aluminum Acetate Topical Solution USP Aluminum Chloride USP Aluminum Chlorohydrate USP Aluminum Chlorohydrate Solution USP Aluminum Chlorohydrex Polyethylene Glycol USP Aluminum Chlorohydrex Propylene Glycol USP Aluminum Dichlorohydrate USP Aluminum Dichlorohydrate Solution USP Aluminum Dichlorohydrex Polyethylene Glycol USP Aluminum Dichlorohydrex Propylene Glycol USP Aluminum Hydroxide Gel USP Dried Aluminum Hydroxide Gel
    [Show full text]
  • Supplement 12
    '95 15TH EDITION U.S DEPARTMENT OF HEALTH AND HUMAN$iER\WIC;ES PUBUC HEALTH SERVICE FOOD AND DRUG ADMINISTRATION CENTER FOR DRUG EVALUATION ANDHESEAlRCH OFFICE OF MANAGEMENT . IJIVISION OF DRUG INFORMATION RESOURCES SUBSCRIBE NOW! Available in March 1996 New 16th Edition APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS 16lli EDITION 1996 CONTENTS • Prescription Drug Product List .' • OTC Drug Product List • Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List • Discontinued Drug Product List • USP Monograph Title Additions or Changes • Orphan Drug Product Designations • Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution • Biopharmaceutic Guidance Availability • ANDA Suitability Petitions • Patent and Exclusivity Information See Subscription Form Inside Back Cover APPROVED DRUG PRODUCTS with THERAPEUTIC EQUIVALENCE EVALUATIONS 15TH EDITION Cumulative Supplement 12 DECEMBER 1995 CONTENTS PAGE 1.0 INTRODUCTION.............................................. iii 1 .1 How to Use the Cumulative Supplement ........................... iii 1.2 Court Order Affecting Uruguay Round Agreements Act-Extended Patents .... iv 1.3 Products Requiring Revised Labeling for Full Approval . v 1.4 Applicant Name Changes . vi 1.5 Availability of the Publication and Updating Procedures . vii 1.6 Report of Counts for the Prescription Drug Product List. viii 2.0 DRUG PRODUCT LISTS ........................................ 2.1 Prescription Drug Product List ................................. 2.2 OTC Drug Product List ...................................... 68 2.3 Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research List ..... 73 2.4 Orphan Drug Product Designations .............................. 74 2.5 Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution ...............
    [Show full text]